{"id":"ticagrelor-alone","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Ticagrelor alone","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:05:48.808928+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:05:55.417747+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ticagrelor alone","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:05:56.319434+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Purinergic receptor P2Y12 negative allosteric modulator","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:05:56.877373+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL398435/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:05:56.785474+00:00"}},"_dailymed":null,"_scrapedAt":"2026-03-28T00:12:35.884Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:05:58.671096+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT07495969","phase":"NA","title":"Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR）","status":"NOT_YET_RECRUITING","sponsor":"Feng Gao","startDate":"2026-04-01","conditions":"Symptomatic Non-acute Intracranial Artery Occlusion, Ischemic Stroke","enrollment":286},{"nctId":"NCT05149560","phase":"PHASE2","title":"Ticagrelor Monotherapy After Stenting","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2021-12-14","conditions":"Acute Myocardial Infarction","enrollment":200},{"nctId":"NCT07257198","phase":"PHASE3","title":"Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone","status":"RECRUITING","sponsor":"Montreal Heart Institute","startDate":"2026-03-03","conditions":"NSTEMI - Non-ST Segment Elevation MI, STEMI (ST Elevation MI), Myocardial Infarction","enrollment":2570},{"nctId":"NCT05531474","phase":"NA","title":"Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2020-11-02","conditions":"Cardiovascular Complication, Bariatric Surgery Candidate","enrollment":200},{"nctId":"NCT05785897","phase":"NA","title":"STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT","status":"RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2025-11-01","conditions":"ST Elevation Myocardial Infarction","enrollment":350},{"nctId":"NCT07374718","phase":"NA","title":"Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Northern Hospital","startDate":"2026-03-01","conditions":"Acute Coronary Syndrome (ACS), High Bleeding Risk(HBR), Coronary Artery Disease (CAD)","enrollment":468},{"nctId":"NCT06535568","phase":"NA","title":"Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)","status":"RECRUITING","sponsor":"Fondazione Ricerca e Innovazione Cardiovascolare ETS","startDate":"2026-01-10","conditions":"Coronary Disease, Heart Diseases, Cardiovascular Diseases","enrollment":576},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":"Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease","enrollment":654},{"nctId":"NCT04045665","phase":"PHASE3","title":"Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-12-13","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":3200},{"nctId":"NCT05997693","phase":"PHASE3","title":"One-Month DAPT in CABG Patients","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2024-08-15","conditions":"Chronic Coronary Disease","enrollment":700},{"nctId":"NCT05650411","phase":"NA","title":"Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)","status":"NOT_YET_RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2026-03-01","conditions":"Left Main Coronary Artery Stenosis","enrollment":828},{"nctId":"NCT06714526","phase":"NA","title":"Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2025-10-07","conditions":"Intracranial Atherosclerosis","enrollment":100},{"nctId":"NCT05782270","phase":"PHASE4","title":"Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-04-11","conditions":"Anticoagulation, Coronary Endarterectomy","enrollment":202},{"nctId":"NCT07164859","phase":"PHASE3","title":"Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI","status":"NOT_YET_RECRUITING","sponsor":"Vincent ROULE","startDate":"2025-10","conditions":"Coronary Artery Disease (CAD), Percutaneous Coronary Intervention (PCI), Antiplatelet Therapy","enrollment":1700},{"nctId":"NCT03869268","phase":"PHASE4","title":"The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2019-04-24","conditions":"Acute Coronary Syndrome","enrollment":72},{"nctId":"NCT03560310","phase":"PHASE4","title":"Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2018-06-29","conditions":"Acute Coronary Syndrome","enrollment":2201},{"nctId":"NCT04360720","phase":"PHASE3","title":"Percutaneous Coronary Intervention Followed by Antiplatelet Monotherapy in the Setting of Acute Coronary Syndromes","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2020-10-15","conditions":"Acute Coronary Syndrome","enrollment":3410},{"nctId":"NCT03430661","phase":"PHASE1","title":"A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2018-01-24","conditions":"Healthy","enrollment":77},{"nctId":"NCT03971500","phase":"NA","title":"1-month vs 12-month DAPT for ACS Patients Who Underwent PCI Stratified by IVUS: IVUS-ACS and ULTIMATE-DAPT Trials","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2019-08-20","conditions":"Coronary Artery Disease","enrollment":3710},{"nctId":"NCT03465644","phase":"PHASE4","title":"TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI","status":"COMPLETED","sponsor":"Duk-Woo Park, MD","startDate":"2019-02-12","conditions":"Coronary Stenoses","enrollment":2018},{"nctId":"NCT06509893","phase":"PHASE4","title":"Ticagrelore Alone Post PCI","status":"RECRUITING","sponsor":"Shiraz University of Medical Sciences","startDate":"2024-08-01","conditions":"Coronary Artery Disease","enrollment":5400},{"nctId":"NCT05952206","phase":"PHASE3","title":"Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy","status":"RECRUITING","sponsor":"iVascular S.L.U.","startDate":"2023-10-13","conditions":"Coronary Artery Disease","enrollment":2312},{"nctId":"NCT06943586","phase":"NA","title":"Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-09","conditions":"Stroke, Transient Ischemic Attack (TIA)","enrollment":200},{"nctId":"NCT06554821","phase":"PHASE1","title":"A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-08-05","conditions":"Healthy Participants","enrollment":28},{"nctId":"NCT05767723","phase":"PHASE4","title":"Platelet Sub-study of the Neomindset Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-02-06","conditions":"Acute Coronary Syndrome","enrollment":48},{"nctId":"NCT06826144","phase":"NA","title":"Chronic Remote Ischemic Conditioning in Small Infarctions Associated with Stent-assisted Coiling of Unruptured Intracranial Aneurysms","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-02-20","conditions":"Unruptured Intracranial Aneurysm, Infarction Cerebral","enrollment":84},{"nctId":"NCT04505774","phase":"PHASE4","title":"Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE","status":"COMPLETED","sponsor":"Matthew Neal MD","startDate":"2020-09-04","conditions":"Covid19","enrollment":3591},{"nctId":"NCT03606642","phase":"PHASE2","title":"SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy","status":"TERMINATED","sponsor":"HonorHealth Research Institute","startDate":"2018-11-19","conditions":"Coronary Artery Disease, Atherosclerosis, Stent Placement","enrollment":50},{"nctId":"NCT03729401","phase":"PHASE4","title":"Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND","status":"SUSPENDED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2019-08-22","conditions":"Coronary Artery Disease, Myocardial Infarction","enrollment":390},{"nctId":"NCT05476081","phase":"","title":"A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA","status":"COMPLETED","sponsor":"University of L'Aquila","startDate":"2021-02-03","conditions":"Ischemic Stroke, TIA","enrollment":2239},{"nctId":"NCT05043610","phase":"PHASE3","title":"MSCs for Prevention of MI-induced HF","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2021-09-15","conditions":"Myocardial Infarction, Acute, Myocardial Infarction First, Myocardial Infarction, Anterior Wall","enrollment":420},{"nctId":"NCT03492385","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers","status":"COMPLETED","sponsor":"SFJ Pharmaceuticals, Inc.","startDate":"2018-04-03","conditions":"Healthy","enrollment":64},{"nctId":"NCT04286438","phase":"PHASE3","title":"Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure","status":"COMPLETED","sponsor":"SFJ Pharmaceuticals, Inc.","startDate":"2020-07-15","conditions":"Hemorrhage, Urgent Surgery, Invasive Procedure","enrollment":226},{"nctId":"NCT06613191","phase":"PHASE4","title":"Colonoscopy and Antiplatelet Therapy Trial","status":"NOT_YET_RECRUITING","sponsor":"Ochsner Health System","startDate":"2024-10-01","conditions":"Coronary Arterial Disease (CAD), Peripheral Vascular Disease","enrollment":100},{"nctId":"NCT05418556","phase":"PHASE4","title":"Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-10-21","conditions":"Coronary Artery Disease","enrollment":3944},{"nctId":"NCT05117866","phase":"NA","title":"Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Meditrix Corp","startDate":"2020-09-15","conditions":"Chronic Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome","enrollment":307},{"nctId":"NCT02886962","phase":"PHASE4","title":"Oral Anticoagulation in Haemodialysis Patients","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2017-07-12","conditions":"Kidney Failure, Chronic","enrollment":50},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT03928353","phase":"PHASE2","title":"Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects","status":"COMPLETED","sponsor":"SFJ Pharmaceuticals, Inc.","startDate":"2019-04-16","conditions":"Healthy","enrollment":23},{"nctId":"NCT05015699","phase":"NA","title":"A Study to Evaluate the Impact of 11-month Ticagrelor Monotherapy Following One-month DAPT After PCI","status":"WITHDRAWN","sponsor":"Sino Medical Sciences Technology Inc.","startDate":"2021-09","conditions":"Coronary Artery Disease","enrollment":""},{"nctId":"NCT04122170","phase":"PHASE2","title":"Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old","status":"COMPLETED","sponsor":"SFJ Pharmaceuticals, Inc.","startDate":"2019-09-24","conditions":"Healthy","enrollment":207},{"nctId":"NCT06058130","phase":"NA","title":"Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-29","conditions":"Acute Ischemic Stroke, Atrial Fibrillation, Stenosis, Carotid","enrollment":2171},{"nctId":"NCT06015477","phase":"NA","title":"Stent-Assisted Coiling Followed by Ticagrelor Monotherapy Instead of Dual Antiplatelet Therapy in Unruptured Intracranial Aneurysm","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-01","conditions":"Intracranial Aneurysm, Stent Complication","enrollment":180},{"nctId":"NCT04442919","phase":"PHASE4","title":"Influence of METHoxyflurane on ANtiplatelet Effect of Ticagrelor in Patients With Unstable Angina Pectoris","status":"COMPLETED","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2020-06-01","conditions":"Unstable Angina","enrollment":72},{"nctId":"NCT05750758","phase":"NA","title":"Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty","status":"COMPLETED","sponsor":"Henan Institute of Cardiovascular Epidemiology","startDate":"2023-02-20","conditions":"Acute Coronary Syndrome","enrollment":140},{"nctId":"NCT06233266","phase":"PHASE1","title":"Ticagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-06-18","conditions":"Healthy Subjects","enrollment":36},{"nctId":"NCT05162131","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers","status":"TERMINATED","sponsor":"SFJ Pharmaceuticals, Inc.","startDate":"2021-12-25","conditions":"Healthy","enrollment":34},{"nctId":"NCT04588727","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-10-15","conditions":"Cardiovascular Disease","enrollment":103},{"nctId":"NCT05093790","phase":"PHASE2","title":"A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-03-25","conditions":"Coronary Artery Disease, Healthy Participants","enrollment":58},{"nctId":"NCT06088433","phase":"PHASE4","title":"Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease","status":"UNKNOWN","sponsor":"Fu Wai Hospital, Beijing, China","startDate":"2023-11-15","conditions":"Coronary Heart Disease","enrollment":292},{"nctId":"NCT05885932","phase":"NA","title":"Drug-eluting Stenting Versus Medical Treatment for Extracranial Vertebral Artery Stenosis","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-08-25","conditions":"Ischemic Stroke, Vertebral Artery Stenosis","enrollment":472},{"nctId":"NCT04927949","phase":"PHASE4","title":"Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2021-06-08","conditions":"ST-elevation Myocardial Infarction","enrollment":128},{"nctId":"NCT04981041","phase":"PHASE4","title":"Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2021-12-16","conditions":"Acute Coronary Syndrome, Atrial Fibrillation","enrollment":2334},{"nctId":"NCT05821062","phase":"","title":"Antiplatelet Therapies in Patients With Depression and Coronary Disease","status":"UNKNOWN","sponsor":"Centro Cardiologico Monzino","startDate":"2022-04-14","conditions":"Coronary Artery Disease, Depression","enrollment":400},{"nctId":"NCT04766437","phase":"PHASE2","title":"Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-02-19","conditions":"Non ST Segment Elevation Acute Coronary Syndrome","enrollment":75},{"nctId":"NCT04949516","phase":"PHASE4","title":"Mono Antiplatelet and Colchicine Therapy","status":"COMPLETED","sponsor":"Wonkwang University Hospital","startDate":"2021-06-15","conditions":"Acute Coronary Syndrome, Drug-Eluting Stents","enrollment":200},{"nctId":"NCT04941196","phase":"PHASE1","title":"Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition","status":"COMPLETED","sponsor":"University of Karachi","startDate":"2020-10-16","conditions":"Healthy Individuals","enrollment":30},{"nctId":"NCT05474053","phase":"PHASE3","title":"Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence","status":"COMPLETED","sponsor":"Cairo University","startDate":"2021-11-13","conditions":"Cardiovascular Diseases, Acute Coronary Syndrome","enrollment":29},{"nctId":"NCT03789916","phase":"PHASE3","title":"SAPT Versus DAPT in Incomplete Revascularization After CABG","status":"RECRUITING","sponsor":"Campus Bio-Medico University","startDate":"2019-01-02","conditions":"Coronary Artery Disease","enrollment":800},{"nctId":"NCT03718429","phase":"PHASE4","title":"Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-14","conditions":"Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation","enrollment":86},{"nctId":"NCT02335099","phase":"PHASE1, PHASE2","title":"Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2014-12","conditions":"End Stage Renal Disease, Vascular Access Patency","enrollment":54},{"nctId":"NCT05373277","phase":"PHASE1","title":"KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug","status":"UNKNOWN","sponsor":"Helsinki University Central Hospital","startDate":"2022-05-11","conditions":"Pharmacokinetics","enrollment":10},{"nctId":"NCT04568083","phase":"","title":"Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-09-25","conditions":"Myocardial Infarction (MI)","enrollment":7035},{"nctId":"NCT05283356","phase":"PHASE4","title":"Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation","status":"UNKNOWN","sponsor":"Fundacin Biomedica Galicia Sur","startDate":"2022-01-21","conditions":"Severe Aortic Valve Stenosis, Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement (TAVR)","enrollment":1206},{"nctId":"NCT04131959","phase":"NA","title":"Ticagrelor CytoSorb Hemoadsorption","status":"TERMINATED","sponsor":"CytoSorbents, Inc","startDate":"2019-10-29","conditions":"Emergent Cardiothoracic Surgery, Bleeding, Drug Removal","enrollment":5},{"nctId":"NCT02817789","phase":"PHASE3","title":"Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI)","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2016-05-09","conditions":"Aortic Valve Stenosis","enrollment":50},{"nctId":"NCT04625764","phase":"NA","title":"Ticagrelor Removal Study Using CytoSorb® 300 mL Device During CPB in Patients Undergoing Emergent Cardiothoracic Surgery","status":"TERMINATED","sponsor":"CytoSorbents Europe GmbH","startDate":"2021-02-23","conditions":"Acute Coronary Syndrome","enrollment":6},{"nctId":"NCT04001894","phase":"PHASE4","title":"Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease","status":"COMPLETED","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2019-07-02","conditions":"Platelet Reactivity","enrollment":50},{"nctId":"NCT03679091","phase":"PHASE4","title":"Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.","status":"COMPLETED","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2018-08-29","conditions":"Platelet Reactivity","enrollment":36},{"nctId":"NCT04088123","phase":"","title":"Impact of Anti-platelet Drug Exposure on Platelet mRNA Splicing in Healthy Subjects","status":"WITHDRAWN","sponsor":"George Washington University","startDate":"2020-04-01","conditions":"Thrombosis; Artery","enrollment":""},{"nctId":"NCT01947959","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":665533},{"nctId":"NCT02468102","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-15","conditions":"Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism","enrollment":99999},{"nctId":"NCT01947985","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-02-01","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":208958},{"nctId":"NCT01947998","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":50299},{"nctId":"NCT03884530","phase":"PHASE3","title":"Ticagrelol Versus Aspirin in Ischemic Stroke","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2019-05-01","conditions":"Acute Stroke, Ischemic Stroke","enrollment":169},{"nctId":"NCT04995159","phase":"NA","title":"Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System","status":"NOT_YET_RECRUITING","sponsor":"Lepu Medical Technology (Beijing) Co., Ltd.","startDate":"2021-09","conditions":"Coronary Heart Disease","enrollment":2150},{"nctId":"NCT04962451","phase":"PHASE4","title":"Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2017-09-01","conditions":"Cerebrovascular Accident, Cerebrovascular Accident, Acute","enrollment":13000},{"nctId":"NCT03492931","phase":"PHASE1","title":"PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-03-28","conditions":"Sickle Cell Disease","enrollment":21},{"nctId":"NCT03533153","phase":"PHASE1, PHASE2","title":"Intravenous MSC Therapy on Ischemia-Reperfusion Injury in Patients With Myocardial Infarction","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2021-03-01","conditions":"Myocardial Infarction","enrollment":90},{"nctId":"NCT04754789","phase":"PHASE3","title":"Effect of Upstream Treatment With High Intensity Statin on the Outcomes of STMI Patients Treated With PPCI","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-02-20","conditions":"ST Elevation Myocardial Infarction","enrollment":160},{"nctId":"NCT01740479","phase":"NA","title":"Complete vs Culprit-only Revascularization to Treat Multi-vessel Disease After Early PCI for STEMI","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2013-02-01","conditions":"Acute Myocardial Infarction, Coronary Artery Disease","enrollment":4042},{"nctId":"NCT04654026","phase":"","title":"the Safety and Efficacy of Antiplatelet Therapy in Patients of CAA","status":"UNKNOWN","sponsor":"Shenzhen Second People's Hospital","startDate":"2021-02-20","conditions":"Cerebral Amyloid Angiopathy","enrollment":43},{"nctId":"NCT02270242","phase":"PHASE4","title":"Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2015-07","conditions":"Cardiovascular Disease, Interventional Cardiology","enrollment":9006},{"nctId":"NCT02618837","phase":"PHASE4","title":"Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2015-12-14","conditions":"Unstable Angina or Non ST Elevated Myocardial Infarction","enrollment":2520},{"nctId":"NCT02271022","phase":"","title":"Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-02-17","conditions":"Acute Coronary Syndromes","enrollment":2000},{"nctId":"NCT02605447","phase":"PHASE4","title":"EVOLVE Short DAPT Study","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2016-02-16","conditions":"Coronary Artery Disease","enrollment":2009},{"nctId":"NCT04548401","phase":"","title":"Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage","status":"UNKNOWN","sponsor":"Nanjing Medical University","startDate":"2019-11-01","conditions":"Aneurysmal Subarachnoid Hemorrhage","enrollment":200},{"nctId":"NCT03008083","phase":"PHASE4","title":"Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation","status":"UNKNOWN","sponsor":"Shanghai MicroPort Medical (Group) Co., Ltd.","startDate":"2019-01-10","conditions":"Drug-Eluting Stents, Percutaneous Coronary Intervention","enrollment":2446},{"nctId":"NCT04501900","phase":"PHASE4","title":"The 3 Years vs 1 Year DAPT After XINSORB BRS Implantation","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-10","conditions":"Cardiovascular Diseases","enrollment":2106},{"nctId":"NCT04293172","phase":"PHASE3","title":"Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2020-06-30","conditions":"Sickle Cell Disease","enrollment":""},{"nctId":"NCT03027934","phase":"PHASE4","title":"A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response","status":"WITHDRAWN","sponsor":"CirQuest Labs, LLC","startDate":"2017-08-28","conditions":"Diabetes Mellitus","enrollment":""},{"nctId":"NCT04206176","phase":"PHASE1, PHASE2","title":"The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease","status":"COMPLETED","sponsor":"The University of The West Indies","startDate":"2019-10-01","conditions":"Platelet Dysfunction Due to Drugs","enrollment":25},{"nctId":"NCT03775746","phase":"PHASE4","title":"Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS","status":"UNKNOWN","sponsor":"East and North Hertfordshire NHS Trust","startDate":"2019-01-08","conditions":"Acute Coronary Syndrome","enrollment":150},{"nctId":"NCT02888652","phase":"","title":"Study on the Registration of Coronary Heart Disease Patients Undergoing PCI","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2015-09","conditions":"Coronary Heart Disease","enrollment":1500},{"nctId":"NCT02302508","phase":"PHASE4","title":"Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients","status":"WITHDRAWN","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2019-09-01","conditions":"Diabetes","enrollment":""},{"nctId":"NCT03224923","phase":"PHASE4","title":"A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)","status":"TERMINATED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2017-08-18","conditions":"Stable Coronary Syndrome, Percutaneous Coronary Intervention, Antiplatelet Therapy","enrollment":5},{"nctId":"NCT02169596","phase":"PHASE4","title":"Is Efficacy of PLAtelet Aggregation Inhibition by Ticagrelor Mediated P2Y12 Blockade Dependent Upon Endogenous Endothelial Nitric OXide?","status":"COMPLETED","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2015-06","conditions":"Acute Coronary Syndome","enrollment":74},{"nctId":"NCT02071212","phase":"PHASE2","title":"Compare Ticagrelor vs Clopidogrel on the Reduction of Arterial Stiffness and Wave Reflectionsin Patients With CAD.","status":"COMPLETED","sponsor":"Hellenic Cardiovascular Research Society","startDate":"2014-02","conditions":"Coronary Artery Disease","enrollment":120},{"nctId":"NCT02939248","phase":"PHASE4","title":"Influence of Naloxone on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine","status":"COMPLETED","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2016-10","conditions":"Unstable Angina Pectoris","enrollment":30},{"nctId":"NCT02939235","phase":"PHASE4","title":"Influence of Metoclopramide on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine","status":"COMPLETED","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2016-07","conditions":"Unstable Angina Pectoris","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL398435"},"_approvalHistory":[],"publicationCount":272,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Brilique"],"phase":"marketed","status":"active","brandName":"Ticagrelor alone","genericName":"Ticagrelor alone","companyName":"University Hospital, Bordeaux","companyId":"university-hospital-bordeaux","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:05:58.671096+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}